Adalimumab for nail psoriasis: Efficacy and safety from the first 26Â weeks of a phase 3, randomized, placebo-controlled trial

After 26 weeks of adalimumab treatment, significant improvements were seen in the primary and all ranked secondary end points and in signs and symptoms of moderate-to-severe nail psoriasis versus with placebo and no new safety risks were identified.